Abstract
Although infusion of cryopreserved bone marrow or peripheral blood stem cell is associated with a variety of symptoms, there have been no reports detailing the data of infusion-related toxicities of cryopreserved cord blood (CB) units. We prospectively evaluated the incidence and significance of infusion-related toxicities in 34 adult patients undergoing unrelated CB transplantation. Cryopreserved CB units were thawed and immediately infused, unfiltered, through a central intravenous catheter without further manipulation. Heart rate, blood pressure, oxygen saturation and clinical symptoms were recorded during and after infusion. Twenty-four percent of patients experienced non-cardiovascular toxicities related to infusion. The incidence of systolic and diastolic hypertension and bradycardia was 58, 64 and 32%, respectively. Although three patients (9%) with severe systolic hypertension after the infusion required treatment with antihypertensive agents, no patients experienced life-threatening side effects or needed discontinuation of CB unit infusion. Patient or transplant characteristics had no effect on the hypertension and bradycardia related to the infusion of CB. These data suggest that infusion of cryopreserved CB without further manipulation after thawing is safe and well tolerated. However, cardiovascular toxicities including hypertension and bradycardia were frequently observed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.
Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.
Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.
Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813–3820.
Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem cell transplantation from related donors in adult patients with hematological malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322–1330.
Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Shimohakamada Y et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 2004; 103: 489–491.
Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92: 10119–10122.
Sauer-Heilborn A, Kadidlo D, McCullough J . Patient care during infusion of hematopoietic progenitor cells. Transfusion 2004; 44: 907–916.
Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW . Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781–786.
Zambelli A, Poggi G, Da Prada G, Pedrazzoli P, Cuomo A, Miotti D et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705–4708.
Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay NK, McCullough J . Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 1991; 31: 521–526.
Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan S . Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 2007; 36: 95–101.
Alessandrino P, Bernasconi P, Caldera D, Colombo A, Bonfichi M, Malcovati L et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplant 1999; 23: 533–537.
Milone G, Mercurio S, Strano A, Leotta S, Pinto V, Battiato K et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapy 2007; 9: 348–355.
Styler MJ, Topolsky DL, Crilley PA, Covalesky V, Bryan R, Bulova S et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant 1992; 10: 435–438.
Keung YK, Lau S, Elkayam U, Chen SC, Douer D . Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant 1994; 14: 363–367.
López-Jiménez J, Cerveró C, Muñoz A, Hernández-Madrid A, Fernández Pineda J, GarcÃa Laraña J et al. Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. Bone Marrow Transplant 1994; 13: 789–793.
Calmels B, Lemarie C, Esterni B, Malugani C, Charbonnier A, Coso D et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47: 1268–1275.
Nagamura-Inoue T, Shioya M, Sugo M, Cui Y, Takahashi A, Tomita S et al. Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank. Transfusion 2003; 43: 1285–1294.
Donmez A, Zoghi M, Cagirgan S, Acarlar C, Tombuloglu M . The effect of hematopoietic progenitor cells' temperature on cardiac arrhythmias in patients given peripheral blood progenitor cells. Transfus Apher Sci 2006; 34: 245–251.
McKenna DH, Wagner JE, McCullough JJ . Umbilical cord blood infusions are associated with mild reactions and are overall well-tolerated. Cytotherapy 2003; 5: 438 (abstr. 11).
Hahn T, Bunworasate U, George MC, Bir AS, Chinratanalab W, Alam AR et al. Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transplant 2003; 32: 145–150.
Petropoulou AD, Bellochine R, Norol F, Marie JP, Rio B . Coronary artery spasm after infusion of cryopreserved cord blood cells. Bone Marrow Transplant 2007; 40: 397–398.
Syme R, Bewick M, Stewart D, Porter K, Chadderton T, Glück S . The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135–141.
Acknowledgements
We thank the medical and nursing staff for taking care of the patients in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Konuma, T., Ooi, J., Takahashi, S. et al. Cardiovascular toxicity of cryopreserved cord blood cell infusion. Bone Marrow Transplant 41, 861–865 (2008). https://doi.org/10.1038/sj.bmt.1705993
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705993
Keywords
This article is cited by
-
A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric patient
Bone Marrow Transplantation (2017)
-
Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion
Bone Marrow Transplantation (2014)
-
Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide
Cell and Tissue Banking (2012)